Anti-Cdc13 antibody [6F11/2] (ab10873)
Key features and details
- Mouse monoclonal [6F11/2] to Cdc13
- Suitable for: WB, IP
- Isotype: IgG2a
Overview
-
Product name
Anti-Cdc13 antibody [6F11/2] -
Description
Mouse monoclonal [6F11/2] to Cdc13 -
Host species
Mouse -
Tested applications
Suitable for: WB, IPmore details -
Immunogen
Full length native protein (purified).
-
General notes
Cdc13 is a fission yeast (S. pombe) B-type M-phase cyclin. Cdc13 binds to Cdk1 (cdc2), and the resulting Cdk1-Cdc13 complex controls the G2/M transition of the cell cycle. 6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Constituent: PBS -
Concentration information loading... -
Purity
Protein A purified -
Primary antibody notes
Cdc13 is a fission yeast (S. pombe) B-type M-phase cyclin. Cdc13 binds to Cdk1 (cdc2), and the resulting Cdk1-Cdc13 complex controls the G2/M transition of the cell cycle. 6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation. -
Clonality
Monoclonal -
Clone number
6F11/2 -
Myeloma
Sp2 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab10873 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
Use at an assay dependent dilution. Predicted molecular weight: 48 kDa.
|
|
| IP |
Use at an assay dependent dilution.
|
| Notes |
|---|
|
WB
Use at an assay dependent dilution. Predicted molecular weight: 48 kDa. |
|
IP
Use at an assay dependent dilution. |
Target
-
Alternative names
- CDC 13 antibody
- G2/mitotic specific cyclin antibody
Protocols
Datasheets and documents
-
Datasheet download
References (6)
ab10873 has been referenced in 6 publications.
- Basu S et al. The Hydrophobic Patch Directs Cyclin B to Centrosomes to Promote Global CDK Phosphorylation at Mitosis. Curr Biol 30:883-892.e4 (2020). PubMed: 32084401
- Rothe C et al. A checkpoint-independent mechanism delays entry into mitosis after UV irradiation. J Cell Sci 130:4028-4037 (2017). PubMed: 29046339
- Uchiyama M et al. The Protein Level of Rev1, a TLS Polymerase in Fission Yeast, Is Strictly Regulated during the Cell Cycle and after DNA Damage. PLoS One 10:e0130000 (2015). PubMed: 26147350
- Bandyopadhyay S et al. The basic leucine zipper domain transcription factor Atf1 directly controls Cdc13 expression and regulates mitotic entry independently of Wee1 and Cdc25 in Schizosaccharomyces pombe. Eukaryot Cell 13:813-21 (2014). Schizosaccharomyces pombe . PubMed: 24728197
- Okuzaki D et al. Spo5 phosphorylation is essential for its own timely degradation and for successful meiosis in Schizosaccharomyces pombe. Cell Cycle 9: (2010). WB ; Schizosaccharomyces pombe . PubMed: 20855961
- Decottignies A et al. In vivo localisation of fission yeast cyclin-dependent kinase cdc2p and cyclin B cdc13p during mitosis and meiosis. J Cell Sci 114:2627-40 (2001). PubMed: 11683390
